GPU dose engine calculated MRI-guided proton plans within 14 seconds
gPRIDE closely matched Monte Carlo calculations for most anatomies and completed MRI-guided proton dose calculations within 13.7 seconds.
Latest
Gold nanoparticles increased proton radiosensitivity without a clear size-dependent effect
Gold nanoparticles increased proton-induced clonogenic killing from 4 Gy onward, with similar sensitization using 20- and 50-nm particles.
Five-fraction prostate SBRT showed low severe toxicity across Austrian centres
Linac-based 40 Gy in five fractions produced low severe toxicity and rapid urinary recovery across seven centres, although follow-up remained short.
Photon robust optimization remains technically promising but poorly standardized
Robust photon planning usually improved uncertainty-resistant target coverage, but modelling, evaluation, and reporting varied substantially across the literature.
Vaginal D2cc predicted late toxicity after EBRT plus cuff brachytherapy
Higher vaginal D2cc and target-dose distribution independently predicted grade 1–2 vaginal toxicity after combined external-beam radiotherapy and cuff brachytherapy.
First on-treatment CBCT best predicted lung radiotherapy response in a small cohort
Adding the first treatment CBCT improved response and survival prediction, while additional scans progressively reduced classification performance.
Surface guidance matched skin marks for breast setup and reduced positioning variability
Single-camera surface guidance provided comparable mean setup accuracy with less variability, while intrafraction breast motion remained below 3 mm in most observations.
Simple phantoms increased students’ reported understanding of radiation medicine
Low-cost diagnostic and treatment phantoms improved students’ self-reported understanding of radiation medicine, although formal learning outcomes were not assessed.
RadComp protons lowered mean cardiac dose without improving early cardiac-related quality of life
Protons substantially reduced mean cardiac exposure, but no cardiac dose metric predicted patient-reported symptoms during the first six months.
Most PLATO quality-of-life deficits recovered by six months, but advanced disease remained burdensome
Most treatment-related deficits improved by six months, although bowel and sexual problems persisted in several standard-dose and locally advanced groups.
Proton therapy reduced estimated immune-cell dose in postoperative esophageal radiotherapy
Estimated immune-cell dose predicted lymphocyte decline and was substantially lower with proton plans, particularly spot-scanning proton arc therapy.
Acuros XB increased synthetic CT dose differences but remained clinically acceptable
Acuros XB was more sensitive than AAA to synthetic CT discrepancies, but target-dose differences remained small in prostate and glioma plans.
Multimodal models appear most promising for predicting rectal cancer pathological complete response
No individual clinical, imaging, blood, or molecular marker reliably predicted pathological complete response, while integrated multimodal models showed greater potential.
Hybrid radiomics model improved tomotherapy PSQA prediction but transferred poorly across centres
Combining plan complexity with three-dimensional dose radiomics improved tomotherapy PSQA prediction, although performance deteriorated substantially during cross-institution testing.
Glioblastoma brachytherapy remains limited by non-standardized dosimetry
Modern intracavitary platforms can intensify pericavitary dose immediately after surgery, but standardized patient-specific dosimetry and comparative clinical evidence remain lacking.